Enterprise Value
-95.21M
Cash
135.6M
Avg Qtr Burn
-6.388M
Short % of Float
0.61%
Insider Ownership
5.01%
Institutional Own.
40.58%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
HB-200 (TheraT® LCMV) + pembrolizumab Details Cancer, Human papillomavirus, Head and neck squamous cell carcinoma | Phase 2 Data readout | |
HB-202/HB-201 Details Cancer, Human papillomavirus | Phase 1/2 Data readout | |
HB-300 Details Cancer, Castration-resistant prostate cancer | Phase 1 Data readout | |
HB-101 (VaxWave®) Details Cytomegalovirus, Infectious disease, Kidney transplantation | Failed Discontinued |